Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Capmatinib Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1865733-40-9, Nvp-inc280-aaa, Capmatinib hydrochloride [usan], C2a374o70x, Capmatinib (dihydrochloride hydrate), Tabrecta
    Molecular Formula
    C23H21Cl2FN6O2
    Molecular Weight
    503.4  g/mol
    InChI Key
    COWBUPJEEDYWKD-UHFFFAOYSA-N
    FDA UNII
    C2A374O70X
    Capmatinib Hydrochloride is the hydrochloride salt form of capmatinib, an orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Capmatinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide;hydrate;dihydrochloride
    2.1.2 InChI
    InChI=1S/C23H17FN6O.2ClH.H2O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20;;;/h2-9,11-13H,10H2,1H3,(H,25,31);2*1H;1H2
    2.1.3 InChI Key
    COWBUPJEEDYWKD-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F.O.Cl.Cl
    2.2 Other Identifiers
    2.2.1 UNII
    C2A374O70X
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzoic Acid

    2. 2-fluoro-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)-(1,2,4)triazin-2-yl)benzamide

    3. 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- B)(1,2,4)triazin-2-yl)benzamide Dihydrochloride Monohydrate

    4. 2-fluoro-n-methyl-4-(7-(quinolin-6-yl-methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

    5. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide

    6. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamide Dihydrochloride

    7. Capmatinib

    8. Capmatinib Dihydrochloride

    9. Capmatinib Dihydrochloride Monohydrate

    10. Capmatinib Hydrochloride Anhydrous

    11. Capmatinib Metabolite M13

    12. Capmatinib Metabolite M18

    13. Cmc-583

    14. Cmc583

    15. Cnj-294

    16. Cnj294

    17. Inc-280

    18. Inc280

    19. Incb-28060

    20. Incb-28060 Free Base

    21. Incb28060

    22. Nvp-inc280

    23. Nvp-inc280-nx

    24. Tabrecta

    2.3.2 Depositor-Supplied Synonyms

    1. 1865733-40-9

    2. Nvp-inc280-aaa

    3. Capmatinib Hydrochloride [usan]

    4. C2a374o70x

    5. Capmatinib (dihydrochloride Hydrate)

    6. Tabrecta

    7. Capmatinib Dihydrochloride Monohydrate

    8. Capmatinib Hydrochloride (usan)

    9. Capmatinib Hydrochloride Hydrate (jan)

    10. 2-fluoro-n-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide Dihydrochloride Hydrate

    11. Capmatinib Hydrochloride Hydrate [jan]

    12. Tabrecta (tn)

    13. Capmatinib 2hcl.h2o

    14. Capmatinib 2hcl Hydrate

    15. Inc-280 Hydrochloride

    16. Incb28060 Hydrochloride

    17. Unii-c2a374o70x

    18. Capmatinib Hydrochloride Hydrate

    19. Chembl3989937

    20. Dtxsid401027869

    21. Hy-13404c

    22. Capmatinib Hydrochloride [who-dd]

    23. Capmatinib Hydrochloride Monohydrate

    24. Cs-0198834

    25. Capmatinib Hydrochloride [orange Book]

    26. D10891

    27. Q27895918

    28. 2-fluoro-n-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2- B)(1,2,4)triazin-2-yl)benzamide Dihydrochloride Monohydrate

    29. Benzamide, 2-fluoro-n-methyl-4-(7-(6-quinolinylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)-, Hydrochloride, Hydrate (1:2:1)

    2.4 Create Date
    2016-11-15
    3 Chemical and Physical Properties
    Molecular Weight 503.4 g/mol
    Molecular Formula C23H21Cl2FN6O2
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count4
    Exact Mass502.1087075 g/mol
    Monoisotopic Mass502.1087075 g/mol
    Topological Polar Surface Area86.1 Ų
    Heavy Atom Count34
    Formal Charge0
    Complexity637
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count4
    4 Drug and Medication Information
    4.1 Drug Indication

    Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    L01EX17